Sebastian J Schober
Overview
Explore the profile of Sebastian J Schober including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
208
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gassmann H, Thiede M, Weiss J, Biele E, Flohe L, Lachermaier H, et al.
Front Immunol
. 2024 Dec;
15:1347404.
PMID: 39723214
Introduction: Pediatric sarcomas, including osteosarcoma (OS), Ewing sarcoma (EwS) and rhabdomyosarcoma (RMS) carry low somatic mutational burden and low MHC-I expression, posing a challenge for T cell therapies. Our previous...
2.
von Ofen A, Thiel U, Eck J, Gassmann H, Thiede M, Hauer J, et al.
Front Oncol
. 2024 Feb;
14:1304374.
PMID: 38357194
Oncolytic viruses (OVs) selectively replicate in tumor cells resulting in lysis, spreading of new infectious units and induction of antitumor immune responses through abrogating an immunosuppressive tumor microenvironment (TME). Due...
3.
Schober S, Thiede M, Gassmann H, von Ofen A, Knoch P, Eck J, et al.
Front Immunol
. 2024 Feb;
15:1330868.
PMID: 38318175
Background: Ewing sarcoma (EwS) is an aggressive and highly metastatic bone and soft tissue tumor in pediatric patients and young adults. Cure rates are low when patients present with metastatic...
4.
Koch J, Schober S, Hindupur S, Schoning C, Klein F, Mantwill K, et al.
Nat Commun
. 2022 Aug;
13(1):4689.
PMID: 35948546
CDK4/6 inhibitors (CDK4/6i) and oncolytic viruses are promising therapeutic agents for the treatment of various cancers. As single agents, CDK4/6 inhibitors that are approved for the treatment of breast cancer...
5.
Biele E, Schober S, Prexler C, Thiede M, von Heyking K, Gassmann H, et al.
Cells
. 2021 Nov;
10(11).
PMID: 34831294
Ewing's sarcoma (EwS) is a pediatric solid tumor entity with low somatic mutational burden and a low rate of tumor-infiltrating T cells, indicating a low extent of immunogenicity. In EwS,...
6.
Gassmann H, Schneider K, Evdokimova V, Ruzanov P, Schober S, Xue B, et al.
Cells
. 2021 Aug;
10(8).
PMID: 34440851
Ewing sarcoma (EwS) is an aggressive pediatric cancer of bone and soft tissues characterized by scant T cell infiltration and predominance of immunosuppressive myeloid cells. Given the important roles of...
7.
Grunewald T, Alonso M, Avnet S, Banito A, Burdach S, Cidre-Aranaz F, et al.
EMBO Mol Med
. 2020 Oct;
12(11):e11131.
PMID: 33047515
Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers. Although constituting only 1% of all human malignancies, sarcomas represent the second most common type of solid tumors in...
8.
Schober S, Thiede M, Gassmann H, Prexler C, Xue B, Schirmer D, et al.
Cells
. 2020 Jul;
9(7).
PMID: 32610710
In this study we report the functional comparison of T cell receptor (TCR)-engineered major histocompatibility complex (MHC) class I-restricted CD4 versus CD8 T cells targeting a peptide from (STEAP1) in...
9.
Donor lymphocyte infusions in adolescents and young adults for control of advanced pediatric sarcoma
Schober S, von Luettichau I, Wawer A, Steinhauser M, Salat C, Schwinger W, et al.
Oncotarget
. 2018 Jun;
9(32):22741-22748.
PMID: 29854312
Background: Allogeneic stem cell transplantation (allo-SCT) and donor lymphocyte infusions (DLI) may induce a graft-versus-tumor effect in pediatric sarcoma patients. Here, we describe general feasibility, toxicity and efficacy of DLI...
10.
Thiel U, Schober S, Einspieler I, Kirschner A, Thiede M, Schirmer D, et al.
Oncoimmunology
. 2017 Jun;
6(5):e1312239.
PMID: 28638739
: Chondromodulin-I (CHM1) sustains malignancy in Ewing sarcoma (ES). Refractory ES carries a dismal prognosis and patients with bone marrow (BM) metastases do not survive irrespective of therapy. We assessed...